Stockscreener 앱 받기
7.37
0.27%
0.02
Sagimet Biosciences Inc 주식(SGMT)의 최신 뉴스
Sagimet Biosciences(SGMT) Stock Options Chain | Quotes & News - Moomoo
Price to earnings forward of Sagimet Biosciences Inc.Series A – NASDAQ:SGMT - TradingView
Enterprise value to EBIT forward of Sagimet Biosciences Inc. Class A – SWB:0O2 - TradingView
Sagimet Biosciences (SGMT) Financials 2026Income Statement and Balance Sheet - MarketBeat
Sagimet Biosciences to join Russell 3000 and Russell 2000 as part of 2026 index reconstitution - Traders Union
JonesTrading Maintains Sagimet Biosciences(SGMT.US) With Buy Rating, Raises Target Price to $31 - Moomoo
Sagimet Therapeutics: Buy Rating Affirmed as Clinically De‑Risked FASN Franchise Advances; Price Target Raised to $31 - TipRanks
Sagimet Biosciences Inc.(NasdaqGM:SGMT) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
Sagimet Biosciences Inc.(NasdaqGM: SGMT) added to Russell 2500 Growth Benchmark - marketscreener.com
Sagimet Biosciences Added to Russell Indexes - marketscreener.com
Sagimet Biosciences Inc.(NasdaqGM: SGMT) added to Russell 2000 Index - marketscreener.com
Sagimet Biosciences added to Russell 2000 and 3000 indexes By Investing.com - Investing.com South Africa
Sagimet Biosciences Inc.(NasdaqGM: SGMT) added to Russell 2000 Value Benchmark - marketscreener.com
Sagimet Biosciences Inc. Class A Actuals & Estimates (NASDAQ:SGMT) - TradingView
Sagimet Biosciences Inc.(NasdaqGM:SGMT) added to Russell Microcap Growth Benchmark Index - marketscreener.com
Sagimet Biosciences (SGMT) Joins Russell 3000 and Russell 2000 I - GuruFocus
Sagimet Biosciences added to Russell 2000 and 3000 indexes - Investing.com
Sagimet Biosciences Inc.(NasdaqGM: SGMT) added to Russell 2000 Growth Benchmark - marketscreener.com
Sagimet Biosciences Joins the Russell 2000® and Russell 3000® Indexes - GlobeNewswire
Sagimet Biosciences Inc.(NasdaqGM: SGMT) added to Russell 3000E Growth Benchmark - marketscreener.com
Sagimet Biosciences Inc.(NasdaqGM: SGMT) added to Russell 2500 Index - marketscreener.com
Price to earnings forward of Sagimet Biosciences Inc. Class A – LS:A3CPAM - TradingView
Sagimet Biosciences Inc.(NasdaqGM: SGMT) added to Russell 3000E Value Benchmark - marketscreener.com
SGMT Stock Surged 40% And Breached 200-DMA For The First Time In Nearly 3 Months – What’s Got Retail Buzzing? - Stocktwits
Enterprise value to EBITDA forward of Sagimet Biosciences Inc.Series A – NASDAQ:SGMT - TradingView
Enterprise value to EBIT forward of Sagimet Biosciences Inc. Class A – LS:A3CPAM - TradingView
Enterprise value to EBITDA forward of Sagimet Biosciences Inc. Class A – LS:A3CPAM - TradingView
Price to book forward of Sagimet Biosciences Inc.Series A – NASDAQ:SGMT - TradingView
Price to sales forward of Sagimet Biosciences Inc.Series A – NASDAQ:SGMT - TradingView
Enterprise value to revenue forward of Sagimet Biosciences Inc.Series A – NASDAQ:SGMT - TradingView
Price to sales forward of Sagimet Biosciences Inc. Class A – LS:A3CPAM - TradingView
Sagimet Biosciences Inc (SGMT) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
0O2 Forecast — Price Target — Prediction for 2027 - TradingView
SGMT Forecast — Price Target — Prediction for 2027 - TradingView
Sagimet Biosciences (SGMT) Short Interest & Short Float | Updated Jun 2026 - MarketBeat
Sagimet Biosciences Inc (SGMT) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Sagimet Biosciences Announces Participation in Upcoming Investor Conference and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Wall Street Analysts Believe Sagimet Biosciences Inc. (SGMT) Could Rally 298.5%: Here's is How to Trade - Eastern Progress
Sagimet Biosciences Inc.(NasdaqGM:SGMT) added to S&P Biotechnology Select Industry Index - marketscreener.com
Sagimet Biosciences (SGMT) Edges Higher as Biotech Sector Gains MomentumZigzag Correction - dars.gov.et
SGMT Q1 2026 Earnings: Narrower-than-Expected Loss Drives Positive ReactionDividend Growth Analysis - dars.gov.et
SGMT News | SAGIMET BIOSCIENCES INC-A (NASDAQ:SGMT) - ChartMill
Sagimet: Buy Rating Reiterated as Denifanstat Advances and $28 Price Target Remains Unchanged - TipRanks
Wedbush Maintains Sagimet Biosciences(SGMT.US) With Buy Rating, Maintains Target Price $28 - Moomoo
Sagimet Biosciences Inc (SGMT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Sagimet Biosciences Inc (SGMT) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Sagimet Biosciences Inc (SGMT) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
SGMT SEC FilingsSagimet Biosciences Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Sagimet Biosciences Inc (SGMT) Valuation: PE, PB & Fair Value Analysis - TradingKey
Sagimet Biosciences Inc (SGMT) Institutional Confidence - TradingKey
Sagimet Biosciences Inc (SGMT) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Sagimet Biosciences (SGMT) director receives 39,567 stock options grant - Stock Titan
Sagimet Biosciences (SGMT) director receives stock option grant for 39,567 shares - Stock Titan
Director at Sagimet Biosciences (NASDAQ: SGMT) receives 39,567 stock options - Stock Titan
Sagimet Biosciences (SGMT) director receives 39,567 stock options at $6.48 - Stock Titan
Sagimet Biosciences (SGMT) grants director Kemble George 39,567 stock options - Stock Titan
2.64%
자본화:
|
볼륨(24시간):